Literature DB >> 23069116

Cystic fibrosis: management of haemoptysis.

K Hurt1, N J Simmonds.   

Abstract

Haemoptysis is a common complication in cystic fibrosis (CF), occurring in approximately 9% of the population. Massive haemoptysis is associated with older patients, more severe disease and carries a high mortality rate. Despite this there are few robust published studies of effective treatments and knowledge of the precise pathogenesis is limited. Current guidelines for treatment from the Cystic Fibrosis Foundation (CFF) are based on consensus opinion of experts. Patients with massive haemoptysis who do not respond to initial medical treatments should undergo bronchial artery embolization. This will control the bleeding in the majority of cases but recurrence rates are high and there are little data to support long-term improved outcomes. Surgery is a last resort in patients with CF.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23069116     DOI: 10.1016/j.prrv.2012.01.003

Source DB:  PubMed          Journal:  Paediatr Respir Rev        ISSN: 1526-0542            Impact factor:   2.726


  3 in total

1.  Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study.

Authors:  V Thompson; N Mayer-Hamblett; M Kloster; D Bilton; P A Flume
Journal:  J Cyst Fibros       Date:  2015-02-25       Impact factor: 5.482

2.  Clinical outcomes of cystic fibrosis patients with hemoptysis treated with bronchial artery embolization.

Authors:  Marília Amaral Peixoto da Silveira; Patrícia Amaral Peixoto da Silveira; Flávia Gabe Beltrami; Leandro Armani Scaffaro; Paulo de Tarso Roth Dalcin
Journal:  J Bras Pneumol       Date:  2021-08-11       Impact factor: 2.624

3.  Recurrent massive hemoptysis in a patient with cystic fibrosis: balloon assisted Onyx embolization after bronchial artery coil recanalization.

Authors:  Raghav R Mattay; Richard Shlansky-Goldberg; Bryan A Pukenas
Journal:  CVIR Endovasc       Date:  2021-01-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.